Statutory Updates to Branded Prescription Drug Fee Regulations
Built by the Tribune's code from the Federal Register. No AI wrote this page. Published in the Federal Register Jan. 2, 2026. Document 2025-24153. Updated Nov. 16, 2026.
- What it does
This document proposes amendments to regulations regarding the annual fee imposed on covered entities engaged in the business of manufacturing or importing certain branded prescription drugs. In response to the replacement of the Coverage Gap Discount Program with the new Manufacturer Discount Program by the Inflation Reduction Act of 2022, the proposed regulations would make updates regarding the discounts, rebates, and other price concessions used to determine branded prescription drug sales under Medicare Part D and would update for prior statutory changes. These proposed regulations would affect persons engaged in the business of manufacturing or importing certain branded prescription drugs.
The Internal Revenue Service's summary, as published in the Federal Register.
- What it would change
1 part of Title 26 of the Code of Federal Regulations:
- Before this
No earlier Federal Register document under regulation identifier 1545-BR16 since Jan. 1, 2025.
- What happens next and when
Written or electronic comments and requests for a public hearing must be received by March 3, 2026. Requests for a public hearing must be submitted as prescribed in the "Comments and Requests for a Public Hearing" section.
The agency's dates, word for word.
The record as published
| Document number | 2025-24153 |
|---|---|
| Action | Notice of proposed rulemaking. |
| Agencies | Treasury Department; Internal Revenue Service |
| Published | Jan. 2, 2026 |
| Comments close | March 3, 2026 |
| Regulation identifier (RIN) | 1545-BR16 |
| Docket | IRS-2026-0002 |
Source: the Federal Register (public domain). The document in the Federal Register